Rznomics Inc. (KOSDAQ:476830)

Market Cap	826.28B
Revenue	n/a
Net Income	n/a
EPS	n/a
Shares Out	27.87M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	819,710
Open	23,700
Previous Close	24,050
Day's Range	23,500 - 30,200
52-Week Range	19,990 - 122,625
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Rznomics

Rznomics Inc. develops RNA based gene therapies for cancers and intractable diseases. Its development stage product candidates include RZ-001_immune therapy combination product, which is in Phase 1b/2a stage for treating Hepatocellular carcinoma; RZ-001 (GBM) that is in Phase 1/2a stage for Glioblastoma; RZ-003, which is in discovery stage for Alzheimer; RZ-004, a pre-clinical product for Retinitis Pigmentosa; and RZ-005, a discovery stage product to treat Rett Syndrome. Rznomics Inc. was incorporated in 2017 and is headquartered in Seongnam-si...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2017
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 476830

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 1, 2026

Data Sources Report a data error